Related Experiment Video
Updated: Apr 15, 2026
04:50
Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
1.4K
[Update in psoriatic arthritis treatment]
Revue Medicale Suisse
|March 25, 2015
Summary
Psoriatic arthritis, a chronic inflammatory condition affecting up to 40% of psoriasis patients, presents with varied joint involvement. Current and emerging therapies target key cytokines like IL-12/IL-23 and IL-17 for improved patient outcomes.
Area of Science:
- Rheumatology
- Immunology
- Dermatology
Context:
- Psoriatic arthritis (PsA) is a chronic inflammatory disease affecting up to 40% of individuals with skin psoriasis.
- Joint involvement in PsA is heterogeneous, with manifestations overlapping rheumatoid arthritis and spondylarthritis.
Purpose:
- To provide an overview of psoriatic arthritis, including its clinical manifestations, current treatment strategies, and emerging therapeutic targets.
- To highlight the heterogeneity of joint involvement in PsA and its classification within broader spondyloarthritis spectrums.
Summary:
- PsA presents diverse clinical features, impacting peripheral joints or the axial skeleton.
- Initial treatments often include non-steroidal anti-inflammatory drugs and methotrexate, with anti-TNF-alpha therapy used for persistent disease.
- Novel treatments targeting cytokines such as IL-12/IL-23 and IL-17 are under investigation.
Impact:
- Understanding the spectrum of PsA aids in tailored treatment approaches.
- The development of targeted therapies offers new hope for managing this complex condition.
- Advances in understanding PsA pathogenesis are paving the way for more effective and specific treatments.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
721
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
721
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
804
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
804
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
682
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
682
01:29Inflammatory Bowel Disease IV: Pharmacological Management
991
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
991
01:26Peptic Ulcer Disease IV: Management
690
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
690
01:11Genome-wide Association Studies-GWAS
17.0K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
17.0K